Ionis Pharmaceuticals has concluded enrolment in the pivotal cohort (Cohort 1) of its Phase III REVEAL study of obudanersen ...
Ionis Pharmaceuticals IONS announced that it has completed enrollment in cohort 1 of the phase III REVEAL study, which is ...
GlobalData on MSN
Ionis grants Recordati rights to zilganersen for Alexander Disease
Recordati will handle regulatory filings and commercial operations ex-US, including supporting early access initiatives.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has completed enrollment in the pivotal cohort (Cohort 1) ...
The approval of Ionis Pharmaceuticals’ Tryngolza for severe hypertriglyceridemia could spur “substantial growth” for the ...
TRYNGOLZA (olezarsen) is indicated as an adjunct to diet to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is indicated as an adjunct to diet to reduce TG ...
The U.S. Food and Drug Administration (FDA) approved on Wednesday Ionis Pharmaceuticals, Inc.’s IONS Tryngolza (olezarsen) to ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global biopharmaceutical leader, to the Ionis Board of Directors, effective ...
After 35 years of research and development in pharmaceutical products, Ionis began marketing its drugs for the first time in ...
Ionis Pharmaceuticals draws attention after a rare-disease therapy license agreement, keeping its RNA-targeted medicine ...
Two years after its first approval for an ultra-rare lipid disorder, Ionis' Tryngolza has been approved by the FDA for severe ...
On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results